Menu
Share this

PPD Recognized for Strong Relationships with Clinical Research Sites

Cited in CenterWatch survey for innovative technology, patient recruitment and site activation

01 Apr. 2015

RSS

WILMINGTON, N.C., (April 1, 2015) – Pharmaceutical Product Development, LLC (PPD) today announced it has been ranked one of the world’s best contract research organizations (CROs) in sustaining strong relationships with investigative sites to promote efficiency, quality and patient safety in clinical research.

Research sites gave PPD excellent ratings on a series of key success indicators in the CenterWatch 2015 Global Site Survey, published today in CenterWatch Monthly. The survey measured the quality of working relationships between CROs and investigative sites conducting clinical trials in developing life-changing medical treatments. The results build on PPD’s recognition in CenterWatch’s previous survey as having the CRO industry’s best reputation.

“PPD purposefully fosters site relationships that enable investigators to more easily participate successfully in clinical trials, while leveraging our global capabilities, a technology advantage, innovative processes and talented people to reduce drug development time and cost for biopharma clients,” said Paul Colvin, PPD’s executive vice president for global clinical development. “With the growing complexity of clinical trials, PPD is committed to providing sites and clients the global resources required to streamline research to more efficiently deliver positive outcomes for patients.”

More than four of every five survey respondents rated PPD as excellent or good, with nearly 50 percent rating PPD as excellent. Both results were increases from the last CenterWatch site survey. PPD ranked among the top three CROs in 26 of the 37 relationship attributes that 2015 survey respondents were asked to judge.

PPD received high scores for excellence in key areas that sites rated as the most important to successful study conduct: professional, knowledgeable and well-trained monitors/clinical research associates; having organized and prepared study support; easily accessible staff for escalation of issues and providing timely and appropriate resolution; and professional medical staff in clinical operations.

In addition, PPD had high scores for excellence in site management attributes including providing patient recruitment planning and support; clear initiation visits and training; support of initiatives to help sites build stronger relationships with study volunteers; and using technology to make processes more efficient. PPD also received high scores for overall project support; study monitoring support; an efficient query handling process and effectively using communication technologies.

Multiple strategic initiatives underpin PPD’s successful site relationships. For instance, PPD’s site intelligence and activation (SIA) group deploys innovative process improvements toward gaining industry-leading cycle times that offer a competitive advantage in strategic project planning, site activation and, ultimately, enrollment. Since the SIA model was launched in 2012, PPD has achieved a greater than 25 percent reduction in mean and median site activation cycle times (site qualified to site active) and a 15 percent reduction in startup cycle times for the critical measure of final protocol to first patient in.

In addition, the company’s real-time data analytics platform, Preclarus™, combines the process, people and organization of PPD to provide an unprecedented view into clinical trial data and operations. And PPD’s Acurian provides industry-leading services that accelerate patient enrollment and support strategies for data-driven feasibility, site selection and enrollment delivery.

CenterWatch’s 2015 Global Site Survey was conducted from October 2014 through early January 2015. More than 72 percent of the 1,900 clinical research professionals who completed the survey were from North America and Europe, according to CenterWatch, and more than 65 percent of respondents were investigators.

About PPD
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 13,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. 

PPD Contacts

Media:
Ned Glascock
+1 910 558 8760
ned.glascock@ppdi.com

Investors:
Nate Speicher
+1 910 558 6783
nate.speicher@ppdi.com

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s site relationships and services contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; consolidation in the pharmaceutical and biotechnology industries; rapid technological advances that make our services or capabilities less competitive; the ability to control SG&A spending; compliance with drug development regulations; changes in the regulation of the drug development process; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.

Contact Us

Upcoming Tradeshows and Speaker Events

Media Contacts:

Randy Buckwalter Senior Manager, Corporate Communications
PPD
Tel: +1 919 456 4425

Elizabeth Humphrey Corporate Communications Manager
PPD
Tel: +1 910 558 6096

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2017 Pharmaceutical Product Development, LLC. All rights reserved.